Collectively, these results demonstrated that inhibiting LAG-3 with other ICs, or the use of neutralizing mAbs against LAG-3 in patients who have become resistant to PD-1/PD-L1 therapy, might be a practical approach for overcoming tumor resistance to mAb therapies and providing therapeutic advantages to patients with acquired resistance. Here, LAG3 is linked to neoplasm.